Amidst a surge of innovation, the biologics market faces unpredictability over volume needs in drug development. Companies are increasingly turning to CDMOs for flexible operation strategies, to adapt to changing manufacturing demands, and for long-term confidence and security. Discover the crucial factors for success in the volatile biologics market, as they explore: